A randomized, placebo-controlled, international phase 3 clinical study of fenfluramine (FINTEPLA) in patients with Dravet syndrome
Latest Information Update: 18 Feb 2022
At a glance
- Drugs Fenfluramine (Primary)
- Indications Dravet syndrome
- Focus Therapeutic Use
- 21 Jan 2021 New trial record
- 08 Dec 2020 Primary endpoint (change in mean MCSF) has been met, according to results presented at the 74th Annual Meeting of the American Epilepsy Society.
- 08 Dec 2020 Results presented at the 74th Annual Meeting of the American Epilepsy Society